Adverse events · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
VISA‐A (score 0 to 100; 100 = no problems) After 3 months (6 to 12 months) · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
Summary of findings: Injection therapies showed no clear difference in VISA‐A (score 0 to 100; 100 = no problems) At 6 weeks compared with placebo or no injection control (low certainty).
3 findings from 1 review
MD 0.79
5 studies · 200 participants
Low
no estimate extracted
5 studies · 189 participants
Low
MD 0.14
3 studies · 132 participants
Low
Adverse events At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes adverse events At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Pain (VAS; score 0 to 100; 0 = no pain) · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes pain (VAS; score 0 to 100; 0 = no pain) compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Return to sports At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes return to sports At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Patient satisfaction Number of satisfied patients · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes patient satisfaction (number of participants satisfied with their… compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Hip Fracture · post‐menopausal women and older people at risk of osteoporotic fractures
Vitamin D [D2, D3 or 25(OH)D] plus calcium leads to lower persons sustaining new hip fracture (1 year estimate) compared with control or placebo (high certainty).
1 finding from 1 review
Persons sustaining new non‐vertebral fracture (1 year estimate) · post‐menopausal women and older people at risk of osteoporotic fractures
1 finding from 1 review
Fractures: vertebral or deformity · post‐menopausal women and older people at risk of osteoporotic fractures
1 finding from 1 review
New fractures · post‐menopausal women and older people at risk of osteoporotic fractures
Vitamin D [D2, D3 or 25(OH)D] plus calcium leads to lower persons sustaining any new fracture (1 year estimate) compared with control or placebo (high certainty).
1 finding from 1 review
Persons with hypercalcaemia ‐ Vitamin D (D2, D3 or 25(OH)D) plus calcium (1 year estimate) · post‐menopausal women and older people at risk of osteoporotic fractures
Vitamin D [D2, D3 or 25(OH)D] plus calcium showed no clear difference in persons with hypercalcaemia ‐ Vitamin D (D2, D3 or 25(OH)D) plus… compared with control or placebo (low certainty).
1 finding from 1 review
Persons with renal disease (calculi or insufficiency) ‐ Vitamin D (D2, D3 or 25(OH)D) plus calcium (1 year estimate) · post‐menopausal women and older people at risk of osteoporotic fractures
Vitamin D [D2, D3 or 25(OH)D] plus calcium leads to higher persons with renal disease (calculi or insufficiency) ‐ Vitamin D… compared with control or placebo (high certainty).
1 finding from 1 review
Deaths ‐ Vitamin D (D2, D3, 25(OH)D) plus calcium (1 year estimate) · post‐menopausal women and older people at risk of osteoporotic fractures
Vitamin D [D2, D3 or 25(OH)D] plus calcium showed no clear difference in deaths ‐ Vitamin D (D2, D3, 25(OH)D) plus calcium (1 year estimate) compared with control or placebo (high certainty).
1 finding from 1 review
Intervention not reported
Hip fractures at 1 year older people living in the community · older people
The intervention showed no clear difference in hip fractures at 1 year older people living in the community (moderate certainty).
1 finding from 1 review
Intervention not reported
Hip fractures at 1 year older people living in institutions · older people
The intervention showed no clear difference in hip fractures at 1 year older people living in institutions (moderate certainty).
1 finding from 1 review
Intervention not reported
Pelvic fractures at 1 year · older people
The intervention showed no clear difference in pelvic fractures at 1 year (low certainty).
1 finding from 1 review
Intervention not reported
Other fractures at 1 year (excluding pelvis) · older people
The intervention showed no clear difference in other fractures at 1 year (excluding pelvis) (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of falls per 1000 people at 1 year · older people
The intervention showed no clear difference in number of falls per 1000 people at 1 year (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events: skin irritation · older people
1 finding from 1 review
Intervention not reported
Adherence/compliance wearing hip protectors · older people
1 finding from 1 review